- Conditions
- Alzheimer's Disease, Dementia, Down's Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1981 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 589
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, trastuzumab, copper Cu 64-DOTA-trastuzumab, ado-trastuzumab emtansine, laboratory biomarker analysis
- Radiation · Procedure · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Multiple Sclerosis
- Interventions
- N-acetyl Cysteine
- Dietary Supplement
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pain, Nociceptive Pain
- Interventions
- FDG radiotracer, PET/MRI, PET/CT imaging
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Epilepsy
- Interventions
- FDG-PET/fMRI/EEG imaging
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- 18F-FFNP, CTI/Siemens Biograph 40 PET/CT Scanner, Estradiol, 18F-FDG
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Albany, New York • Cleveland, Ohio
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, Sodium Fluoride F-18
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cervical Cancer
- Interventions
- Positron Emission Tomography
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lung Carcinoma, Solitary Pulmonary Nodule, Cigarette Smoking Behavior
- Interventions
- Computed Tomography, fluorodeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Laboratory Biomarker Analysis, Positron Emission Tomography, Positron Emission Tomography (PET)
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Cowden's Disease, Hamartoma Syndrome, Multiple
- Interventions
- fludeoxyglucose F 18, sirolimus, Clinical Videography
- Radiation · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, FDG-Positron Emission Tomography, Glofitamab, Ibrutinib, Magnetic Resonance Imaging, Obinutuzumab
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Ovarian Cancer, High Grade Ovarian Serous
- Interventions
- PET/MRI, Contrast enhanced CT
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- SGN-15, Docetaxel
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Portland, Oregon
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
- Interventions
- [18F]FAPI-74, [18F]FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Childhood Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, magnetic resonance imaging
- Radiation · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Interventions
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Sleep data recording, PET scan - waking, PET scan - REM Sleep
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Fluorothymidine F-18, Irinotecan Hydrochloride, Positron Emission Tomography, Therapeutic Conventional Surgery
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cushing's Disease, Pituitary Adenoma
- Interventions
- Desmopressin acetate
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 8 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Liver Cancer
- Interventions
- 18F-Fluorodeoxyglucose-PET (FDG-PET), 11Carbon-Acetate-PET
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer, Pancreatic Cancer, Rectal Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis, pharmacological study, Cu 64 anti-CEA monoclonal antibody M5A IV
- Procedure · Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
- Conditions
- High-grade Glioma, Brain Metastases, Brain Metastases, Adult
- Interventions
- 68Ga-PSMA-11 PET Scans
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more